1. Home
  2. YDKG vs BIAF Comparison

YDKG vs BIAF Comparison

Compare YDKG & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yueda Digital Holding Class A Ordinary Share

YDKG

Yueda Digital Holding Class A Ordinary Share

N/A

Current Price

$0.82

Market Cap

4.9M

ML Signal

N/A

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

N/A

Current Price

$1.05

Market Cap

4.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
YDKG
BIAF
Founded
2005
2014
Country
China
United States
Employees
N/A
57
Industry
Advertising
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9M
4.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
YDKG
BIAF
Price
$0.82
$1.05
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
67.1K
476.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$20.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.02
$0.16
52 Week High
$3.90
$13.50

Technical Indicators

Market Signals
Indicator
YDKG
BIAF
Relative Strength Index (RSI) 43.34 47.73
Support Level $0.81 $0.92
Resistance Level $1.04 $1.45
Average True Range (ATR) 0.07 0.11
MACD -0.00 0.01
Stochastic Oscillator 10.21 32.61

Price Performance

Historical Comparison
YDKG
BIAF

About YDKG Yueda Digital Holding Class A Ordinary Share

Yueda Digital Holding is a digital-economy company with a focus on the long-term accumulation of mainstream cryptocurrencies. The business activities of the company include active treasury management of mainstream digital assets, exploration of compliant, risk-managed yield opportunities, such as staking, on-chain liquidity provision, and other conservative market activities, selective investments and partnerships in Web3 infrastructure and applications, and advisory services for enterprises entering the digital-asset economy.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Share on Social Networks: